The serological and histological characteristics of drug-induced liver injury patients with autoimmune-like manifestations

Abstract

Abstract: Objective To investigate the serological and histological characteristics of drug-induced liver injury (AL-DILI) patients with autoimmune-like manifestations.Methods Seventy-five DILI patients admitted to hospital between July 2016 and August 2021 were divided into two groups according to whether they had autoimmune manifestations. The basic conditions, serological and histological characteristics of the patients were compared.Results 87.9% of the patients in the observation group were female, which were significantly higher than that of 61.9% in the control group (P<0.05). Comparing the serological characteristics of the observation group and the control group, The levels of AST, GGT, globulin, IgG and IgA in the observation group were 220.0 (79.9, 398.9) U/L, 187.5 (105.8, 299.5) U/L, 30.6 (27.9, 34.1) g/L, 14.9 (12.8, 18.2) g/L and 2.9 (2.3, 3.4) g/L, respectively, which were significantly higher than those of [95.1 (60.3, 276.5) U/L, 104.5 (51.5, 205.5) U/L, 26.3 (24.4, 28.0) g/L, 10.1 (8.7, 12.6) g/L and 2.0 (1.5, 2.8) g/L] in the control group (P<0.05). The level of ChE was 5626 (4812, 7356) U/L in the observation group, which was significantly lower than that of [6981 (5328, 8096) U/L] in the control group (P<0.05). Comparing the histological characteristics of the observation group and the control group, the proportion of eosinophil and/or neutrophil infiltration in the observation group was 54.8%, which was significantly higher than that of 15.2% in the control group (P<0.05).Conclusion The difference of serological and histological characteristics is helpful to distinguish AL-DILI from simple DILI, which provides a theoretical basis for their differential diagnosis.

Key words: Drug-induced liver injury, Autoimmune hepatitis, Histological characteristics

WU Jin-ling, GAO Min. The serological and histological characteristics of drug-induced liver injury patients with autoimmune-like manifestations[J]. Chinese Hepatolgy, 2023, 28(11): 1285-1288.

References

[1] Gerussi A, Natalini A, Antonangeli F, et al. Immune-mediated drug-induced liver injury: immunogenetics and experimental models. Int J Mol Sci, 2021, 22(9).
[2] de la Torre-Alaez M, Inarrairaegui M. Drug liver injury induced by olmesartan mediated by autoimmune-like mechanism: a case report. Eur J Case Rep Intern Med, 2020, 7(1): 001407.
[3] Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland china. Gastroenterology, 2019, 156(8): 2230-2241 e2211.
[4] Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int, 2022, 42(9): 1999-2014.
[5] Bjornsson ES, Navarro VJ, Chalasani N. Liver injury following tinospora cordifolia consumption: drug-induced aih, or de novo aih? J Clin Exp Hepatol, 2022, 12(1): 6-9.
[6] Clinton JW, Kiparizoska S, Aggarwal S, et al. Drug-induced liver injury: highlights and controversies in the recent literature. Drug Saf, 2021, 44(11): 1125-1149.
[7] Floreani A, Bizzaro D, Shalaby S, et al. Sex disparity and drug-induced liver injury. Dig Liver Dis, 2023, 55(1): 21-28.
[8] Zhang J, Xie Q, Kong W, et al. Short-chain fatty acids oppositely altered expressions and functions of intestinal cytochrome p4503a and p-glycoprotein and affected pharmacokinetics of verapamil following oral administration to rats. J Pharm Pharmacol, 2020, 72(3): 448-460.
[9] Teschke R, Danan G. Idiosyncratic Drug induced liver injury, cytochrome p450, metabolic risk factors and lipophilicity: highlights and controversies. Int J Mol Sci, 2021, 22(7).
[10] Yang Y, Ge FL, Tang JF, et al. A review of herb-induced liver injury in mainland china. Front Pharmacol, 2022, 13: 813073.
[11] Ballotin VR, Bigarella LG, Brandao ABM, et al. Herb-induced liver injury: systematic review and meta-analysis. World J Clin Cases, 2021, 9(20): 5490-5513.
[12] Kaplowitz N. Herb-induced liver injury: a global concern. Chin J Integr Med, 2018, 24(9): 643-644.
[13] Bjornsson HK, Bjornsson ES. Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med, 2022, 97: 26-31.
[14] Hassan A, Fontana RJ. The diagnosis and management of idiosyncratic drug-induced liver injury. Liver Int, 2019, 39(1): 31-41.
[15] Clemens MM, McGill MR, Apte U. Mechanisms and biomarkers of liver regeneration after drug-induced liver injury. Adv Pharmacol, 2019, 85: 241-262.